Yuanjing Pharmaceutical

Yuanjing Pharmaceutical, also known as Vision Pharmaceutical, is a core subsidiary of Grandpharma (China Grand Pharmaceutical and Healthcare Holdings Limited) and serves as its primary platform for innovative drug development and commercialization in China. The company focuses on high-barrier therapeutic areas including ophthalmology, precision interventional oncology, and cardiovascular disease. Through strategic global partnerships with companies such as Telix Pharmaceuticals, ITM, and Formosa Pharmaceuticals, Yuanjing has built a robust pipeline of advanced radiopharmaceuticals and innovative ophthalmic treatments. The company is a key player in the Chinese radiopharmaceutical market, managing several late-stage programs and commercialized precision intervention products. Headquartered in Wuhan, Yuanjing is central to Grandpharma's transition into an innovation-led healthcare group.